osimertinib
astrazeneca
['tagrisso', 'nsclc', 'sclc', 'astrazeneca']
astrazeneca s tagrisso reduces the risk of death by 51% as compared with placebo in egfr-mutated nsclc patients.
#astrazeneca #tagrisso #pharma #lifesciences #biospace 
Your source for biopharma news and jobs